Molecular Therapeutics, Inc. (MRx) today announced the formation of Molecular Imaging Products Company (MIP), which will focus on the manufacture and distribution of molecular imaging and related biochemical products to support researchers working in the expanding field of molecular imaging. “We are excited about the formation of this new business unit, which leverages the knowledge and expertise in the field of molecular imaging at MRx and our subsidiary, Molecular Imaging Research, Inc.,” said Dr. Prasad Sunkara, CEO of Molecular Therapeutics, Inc. “The rapidly growing field of molecular imaging combines the remarkable advances in cellular and molecular biology with several imaging technologies, such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) and optical imaging.” Research utilizing molecular imaging employs various novel molecular imaging technologies to non-invasively observe and measure previously invisible biological processes in-vivo (in the body) which could more quickly and efficiently prove efficacy in the treatment of human diseases, such as cancer and arthritis, and diseases of the cardiovascular and central nervous (CNS) systems, etc. Sunkara further stated, “We recognized the need for a primary provider that would be a comprehensive source of compounds, reagents, and supplies for the increasing number of scientists in this exciting field. The mission of MIP is to support the advances in molecular imaging by providing the worldwide community of researchers with a wide array of high-quality products.”
